Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VXRT – Vaxart, Inc.

Vaxart, Inc. - Common Stock
VXRT
$0.4155
Name : Vaxart, Inc. - Common Stock
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $94,820,424.00
EPSttm : -0.33
finviz dynamic chart for VXRT
Vaxart, Inc. - Common Stock
$0.4155
2.59%
$0.0105

Float Short %

5.41

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

-0.03

EPS Last/This Y

EPS This/Next Y

-0.05

Price

0.42

Target Price

4.67

Analyst Recom

1

Performance Q

-41.81

Relative Volume

2.86

Beta

1.25

Ticker: VXRT




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-04-14VXRT0.35150.090.0513009
2025-04-15VXRT0.35540.080.0012909
2025-04-16VXRT0.34890.070.0013001
2025-04-17VXRT0.34090.070.0112956
2025-04-18VXRT0.34390.070.0112956
2025-04-21VXRT0.31760.070.006652
2025-04-22VXRT0.33710.070.006890
2025-04-23VXRT0.34380.070.016927
2025-04-24VXRT0.36070.070.077050
2025-04-25VXRT0.40070.0690072639225180.0158730158730167064
2025-04-28VXRT0.44720.0654166079233050.0476973684210537557
2025-04-29VXRT0.42660.060.248139
2025-04-30VXRT0.43990.070.168379
2025-05-01VXRT0.4290.060.008400
2025-05-02VXRT0.44840.060.008456
2025-05-05VXRT0.41570.060.408595
2025-05-06VXRT0.37450.060.008697
2025-05-07VXRT0.38870.060.008785
2025-05-08VXRT0.40310.060.129084
2025-05-09VXRT0.41980.060.119089
2025-05-12VXRT0.40620.060.009176
2025-05-13VXRT0.41050.060.009212
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-04-14VXRT0.3650.0- -0.34
2025-04-15VXRT0.3650.0- -0.34
2025-04-16VXRT0.3550.0- -0.34
2025-04-17VXRT0.3450.0- -0.34
2025-04-18VXRT0.3450.0- -0.34
2025-04-21VXRT0.3250.0- -0.34
2025-04-22VXRT0.3450.0- -0.34
2025-04-23VXRT0.3450.0- -0.34
2025-04-24VXRT0.3650.0- -0.34
2025-04-25VXRT0.4050.0- -0.34
2025-04-28VXRT0.4550.0- -0.34
2025-04-29VXRT0.4350.0- -0.34
2025-04-30VXRT0.4450.0- -0.34
2025-05-01VXRT0.4350.0- -0.34
2025-05-02VXRT0.4550.0- -0.34
2025-05-05VXRT0.4250.0- -0.34
2025-05-06VXRT0.3850.0- -0.34
2025-05-07VXRT0.3950.0- -0.34
2025-05-08VXRT0.4050.0- -0.34
2025-05-09VXRT0.4250.0- -0.34
2025-05-12VXRT0.4150.0- -0.34
2025-05-13VXRT0.4250.0- -0.34
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-04-14VXRT0.00-15.945.80
2025-04-15VXRT0.00-15.945.80
2025-04-16VXRT0.00-15.945.80
2025-04-17VXRT0.00-15.945.80
2025-04-18VXRT0.00-15.945.80
2025-04-21VXRT0.00-16.035.80
2025-04-22VXRT0.00-16.035.80
2025-04-23VXRT0.00-16.035.80
2025-04-24VXRT0.00-16.035.80
2025-04-25VXRT0.00-16.035.80
2025-04-28VXRT0.00-16.045.91
2025-04-29VXRT0.00-16.045.91
2025-04-30VXRT0.00-16.045.91
2025-05-01VXRT0.00-16.045.91
2025-05-02VXRT0.00-16.045.91
2025-05-05VXRT0.00-16.095.91
2025-05-06VXRT0.00-16.095.91
2025-05-07VXRT0.00-16.095.91
2025-05-08VXRT0.00-16.095.91
2025-05-09VXRT0.00-16.095.91
2025-05-12VXRT0.00-17.155.41
2025-05-13VXRT0.00-17.155.41
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

-0.07

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

Institutional Transactions

-17.15

Beta

1.25

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

24

Growth Score

46

Sentiment Score

38

Actual DrawDown %

98.3

Max Drawdown 5-Year %

-98.7

Target Price

4.67

P/E

Forward P/E

PEG

P/S

3.3

P/B

1.61

P/Free Cash Flow

EPS

-0.35

Average EPS Est. Cur. Y​

-0.34

EPS Next Y. (Est.)

-0.39

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-233.27

Relative Volume

2.86

Return on Equity vs Sector %

-137.3

Return on Equity vs Industry %

-120.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Vaxart, Inc. - Common Stock
Sector: Healthcare
Industry: Biotechnology
Employees: 105
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
stock quote shares VXRT – Vaxart, Inc. Stock Price stock today
news today VXRT – Vaxart, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VXRT – Vaxart, Inc. yahoo finance google finance
stock history VXRT – Vaxart, Inc. invest stock market
stock prices VXRT premarket after hours
ticker VXRT fair value insiders trading